UAB receives cutting-edge robot to diagnose and support treatment of prostate cancer

June 08, 2016

BIRMINGHAM, Ala. - The world-renowned iSR'obotTM Mona Lisa makes its way to the United States, providing urologic surgeons with a tool to diagnose prostate cancer earlier through accurate diagnosis and precise localization that may allow for targeted treatments in the future.

The University of Alabama at Birmingham is one of two beta sites in the United States to receive this new image-guided system. Lead investigator Soroush Rais-Bahrami, M.D., will determine the utility of the equipment for potential clinical use in the setting of the UAB Urologic Oncology Innovations Lab through a pilot pre-clinical project, "Phantom-Based Evaluation of a Novel Trans-Perineal Platform for Prostate Cancer Detection and Treatment."

"As the only hospital in the Southeast to have the Mona Lisa robotic device, our team's input on the device will help shape the future of prostate cancer diagnosis and treatment, not only for our patients at UAB but also patients worldwide," said Rais-Bahrami, assistant professor in UAB's Department of Urology and Department of Radiology. "Our feedback will help modify and make the already successful robot better as it launches in the United States for research and clinical implementation."

The Mona Lisa robotic platform created by Biobot Surgical uses magnetic resonance imaging and ultrasound fusion techniques to robotically guide biopsy of suspicious lesions. The fusion software helps with the localization of the needle when a biopsy procedure is performed, providing pinpoint accuracy. With UAB investigators, the device is being further developed to plan for minimally invasive focal therapy for treating prostate cancer in the future.

Ultimately, the Mona Lisa will be used for focal or targeted therapy through image-guidance and treatment localization for prostate cancer. More than a thousand patients across Europe and Asia are already receiving biopsies with the Mona Lisa robotic device.

"In the United States, we are currently treating the entire prostate for cancer," said Jeffrey Nix, M.D., assistant professor in UAB's Department of Urology. "We have the capability to fuse MRI and ultrasound to identify the exact location of the cancer. We are excited about providing personalized care for each of our patients and look forward to the day that we can administer localized treatment with the use of the Mona Lisa."

The Mona Lisa is being integrated as an investigation by a multidisciplinary team founded and co-directed by Drs. Rais-Bahrami and Nix. The UAB Program for Personalized Prostate Cancer Care combines experts from urology, radiology, radiation oncology, medical oncology and pathology to determine the best treatment pathway for each individual with prostate cancer.

UAB investigators are using phantom studies and 3-D personalized molds of prostates to prove the principle that biopsies with spacial accuracy of certain targeted regions can be performed.

After Biobot receives approval from the United States Food and Drug Administration for the MRI-US Fusion software, UAB looks forward to beginning clinical trials that biopsy-qualified prostate cancer patients could benefit from the use of this device.

Biobot Surgical and BK Medical Systems provided support for the evaluation of this equipment.
-end-
About UAB

Known for its innovative and interdisciplinary approach to education at both the graduate and undergraduate levels, the University of Alabama at Birmingham is the state of Alabama's largest employer and an internationally renowned research university and academic medical center; its professional schools and specialty patient-care programs are consistently ranked among the nation's top 50. UAB's Center for Clinical and Translational Science is advancing innovative discoveries for better health as a two-time recipient of the prestigious Center for Translational Science Award. Find more information at http://www.uab.edu and http://www.uabmedicine.org.

EDITOR'S NOTE: The University of Alabama at Birmingham is a separate, independent institution from the University of Alabama, which is located in Tuscaloosa. Please use University of Alabama at Birmingham on first reference and UAB on all subsequent references.

VIDEO: http://www.youtube.com/uabnews TEXT: http://www.uab.edu/news TWEETS: http://www.twitter.com/uabnews

University of Alabama at Birmingham

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.